New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas
Oncology Research and Treatment · 23.12.2024 · 48 (4) · 186-196
DOI: 10.1159/000543223 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research and Treatment, online erschienen am 23.12.2024. Verfasst von Sophie Joch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Paediatric Haematology-Oncology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria, sophie.joc…. Hauptthemen laut MEDLINE: Neoplasm, Residual, Circulating Tumor DNA, Sarcoma, Translocation, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Assessment of circulating tumor DNA (ctDNA) as a means to monitor disease activity in translocation-associated tumors has become very popular in clinical practice. However, there are still few studies on its clinical application to date. Our study evaluates the clinical applicability of ctDNA as a biomarker for monitoring minimal residual disease (MRD) in patients with translocation-associated sarcomas.
Methods
In this retrospective study, we correlated 285 ctDNA samples from 34 patients diagnosed with translocation-associated sarcoma with the clinical course and images. Blood samples were collected at multiple time points during follow-up (median: 97 weeks, range: 7–398).
Results
We discovered a significant association between ctDNA levels and the clinical course of the disease, particularly noting differences between patients in remission or with progressive disease (p = 0.001). Furthermore, although we noted that ctDNA levels remained undetectable in a few cases of unilocular recurrence (n = 3), they were consistently higher in patients with multilocular recurrence (n = 14; p = 0.008).
Conclusion
Monitoring ctDNA levels provides highly specific, additional information enabling early recurrence detection in patients with translocation-associated sarcomas during the follow-up and can be integrated into clinical practice. However, MRD monitoring by ctDNA quantification alone does not allow the reliable detection of 100% of unilocular recurrences and should be complemented by the use of conventional imaging techniques.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Paediatric Haematology-Oncology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria, sophie.joch@gmail.com.
- Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria.
- Institute of Pathology, Medical University of Graz, Graz, Austria.
- Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Division of Paediatric Haematology-Oncology, Department of Paediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.
Zitieren
APA
Joch, S., Smolle, M. A., Kashofer, K., Thüringer, A., Szkandera, J., Benesch, M., El-Heliebi, A., Liegl-Atzwanger, B., Leithner, A., & Seidel, M. G. (2024). New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas. Oncology Research and Treatment, 48(4), 186-196. https://doi.org/10.1159/000543223
Vancouver
Joch S, Smolle MA, Kashofer K, Thüringer A, Szkandera J, Benesch M, et al. New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas. Oncology Research and Treatment. 2024;48(4):186-196. doi:10.1159/000543223
BibTeX
@article{Joch2024,
author = {Joch, Sophie and Smolle, Maria Anna and Kashofer, Karl and Thüringer, Andrea and Szkandera, Joanna and Benesch, Martin and El-Heliebi, Amin and Liegl-Atzwanger, Bernadette and Leithner, Andreas and Seidel, Markus G},
title = {New Insights from Long-Term Clinical Use of Circulating Tumor DNA-Based Minimal Residual Disease Monitoring in Translocation-Associated Sarcomas},
journal = {Oncology Research and Treatment},
year = {2024},
volume = {48},
number = {4},
pages = {186--196},
doi = {10.1159/000543223}
}
EUVIMED